©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2023; 11(17): 3976-3979
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3976
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3976
Low-dose immunotherapy as a potentiator to increase the response with neo-adjuvant chemotherapy in oral cancers
Narmadha Rathinasamy, Department of Medical Oncology, PSG Institute of Medical Science and Research, Coimbatore 641004, Tamil Nadu, India
Sathish Muthu, Department of Orthopaedics, Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India
Sathish Muthu, Department of Biotechnology, School of Engineering and Technology, Sharda University, New Delhi 201310, Uttar Pradesh, India
Sathish Muthu, Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India
Anand Krishnan, Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa
Author contributions: Rathinasamy N performed the conceptualization; Muthu S did the data curation; Rathinasamy N and Muthu S did the data analysis; the manuscript writing and revision by all authors.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Sathish Muthu, DNB, MS, Research Head, Department of Orthopaedics, Orthopaedic Research Group, Ramanathapuram, Coimbatore 641045, Tamil Nadu, India.
Received: March 17, 2023
Peer-review started: March 17, 2023
First decision: May 12, 2023
Revised: May 12, 2023
Accepted: May 17, 2023
Article in press: May 17, 2023
Published online: June 16, 2023
Processing time: 87 Days and 5.8 Hours
Peer-review started: March 17, 2023
First decision: May 12, 2023
Revised: May 12, 2023
Accepted: May 17, 2023
Article in press: May 17, 2023
Published online: June 16, 2023
Processing time: 87 Days and 5.8 Hours
Core Tip
Core Tip: There is a need to potentiate the effect of neo-adjuvant chemotherapy (NACT) in oral cancers. The utilization of immunotherapy to enhance NACT has been shown to reduce metastasis and recurrence. Hence, the concept of low-dose immunotherapy as a potentiator of NACT could be implemented in routine practice. Moreover, low-dose immunotherapy-enhanced NACT helps us understand the predictors of treatment response.